JP2022548777A5 - - Google Patents
Info
- Publication number
- JP2022548777A5 JP2022548777A5 JP2022518208A JP2022518208A JP2022548777A5 JP 2022548777 A5 JP2022548777 A5 JP 2022548777A5 JP 2022518208 A JP2022518208 A JP 2022518208A JP 2022518208 A JP2022518208 A JP 2022518208A JP 2022548777 A5 JP2022548777 A5 JP 2022548777A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962904272P | 2019-09-23 | 2019-09-23 | |
| US62/904,272 | 2019-09-23 | ||
| PCT/US2020/052121 WO2021061708A1 (en) | 2019-09-23 | 2020-09-23 | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548777A JP2022548777A (ja) | 2022-11-21 |
| JPWO2021061708A5 JPWO2021061708A5 (https=) | 2023-09-06 |
| JP2022548777A5 true JP2022548777A5 (https=) | 2023-09-06 |
| JP7603670B2 JP7603670B2 (ja) | 2024-12-20 |
Family
ID=74881697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518208A Active JP7603670B2 (ja) | 2019-09-23 | 2020-09-23 | マウスおよびヒト線維芽細胞活性化タンパク質（ｆａｐ）と交差反応するイヌ線維芽細胞活性化タンパク質に対するモノクローナル抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12139550B2 (https=) |
| EP (1) | EP4041290A4 (https=) |
| JP (1) | JP7603670B2 (https=) |
| KR (1) | KR20220066090A (https=) |
| CN (1) | CN114761036B (https=) |
| AU (1) | AU2020352986A1 (https=) |
| BR (1) | BR112022005404A2 (https=) |
| CA (1) | CA3151438A1 (https=) |
| IL (1) | IL291341A (https=) |
| MX (1) | MX2022003465A (https=) |
| WO (1) | WO2021061708A1 (https=) |
| ZA (1) | ZA202203460B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| US20240199762A1 (en) * | 2021-04-23 | 2024-06-20 | Philogen S.P.A | Anti-fibroblast activation protein antibodies |
| WO2025005966A1 (en) * | 2023-06-29 | 2025-01-02 | Edge Animal Health, Inc. | Urine pcr assay and use thereof to diagnose and stage feline chronic kidney disease |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| CN118388652B (zh) * | 2024-06-21 | 2025-03-04 | 杭州新东澳生物科技有限公司 | 抗成纤维细胞活化蛋白的单克隆抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ATE446366T1 (de) | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| EP2483316A1 (en) * | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| HUE036077T2 (hu) * | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US20160136272A1 (en) * | 2013-05-14 | 2016-05-19 | Innate Pharma | Methods for restoring corticosteroid sensitivity |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| GB201500875D0 (en) * | 2015-01-19 | 2015-03-04 | Philogen Spa | Antibodies for treatment and diagnosis |
| TWI736575B (zh) | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| MY209117A (en) | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| WO2018105560A1 (ja) * | 2016-12-07 | 2018-06-14 | 国立大学法人大阪大学 | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| US11786551B2 (en) * | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| CN109796532B (zh) | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| MA51428A (fr) | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| KR102804816B1 (ko) | 2018-03-09 | 2025-05-09 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| EP4228601A4 (en) | 2020-10-13 | 2025-08-06 | Univ Pennsylvania | IN VIVO TARGETING OF FIBROSIS BY TARGETING ANTI-CD5 IN MRNA-LNP FAP-CAR-T |
-
2020
- 2020-09-23 WO PCT/US2020/052121 patent/WO2021061708A1/en not_active Ceased
- 2020-09-23 JP JP2022518208A patent/JP7603670B2/ja active Active
- 2020-09-23 KR KR1020227011620A patent/KR20220066090A/ko active Pending
- 2020-09-23 CN CN202080079394.8A patent/CN114761036B/zh active Active
- 2020-09-23 US US17/029,284 patent/US12139550B2/en active Active
- 2020-09-23 BR BR112022005404A patent/BR112022005404A2/pt unknown
- 2020-09-23 MX MX2022003465A patent/MX2022003465A/es unknown
- 2020-09-23 EP EP20869609.6A patent/EP4041290A4/en active Pending
- 2020-09-23 CA CA3151438A patent/CA3151438A1/en active Pending
- 2020-09-23 AU AU2020352986A patent/AU2020352986A1/en active Pending
-
2022
- 2022-03-14 IL IL291341A patent/IL291341A/en unknown
- 2022-03-24 ZA ZA2022/03460A patent/ZA202203460B/en unknown
-
2024
- 2024-02-28 US US18/589,804 patent/US20240384004A1/en active Pending